3 results
Primary Objective:To investigate the safety and tolerability of JNJ-42847922 in subjects with MDD. Study medication will be administered for 10 days in women of childbearing potential (WOCBP) or for 4 weeks in all other subjects.Secondary Objectives…
To provide idelalisib, a marketed PI3K* inhibitor, in lieu of GS-9820, an investigational second generation PI3K* inhibitor, to subjects receiving GS-9820 in Study GS-US-315-0102 at the time of study closure.
PrimaryPart 3 - Repeated doses in atopic dermatitis (AD) patients - PDY16891* To evaluate the safety and tolerability of SAR443726 after repeated SC doses in adult participants with moderate-to-severe ADSecondaryPart 3 - Repeated doses in AD…